Amgen stock (US0311621009): Biotech leader navigates patent cliffs and pipeline momentum

Amgen Inc., a biotech powerhouse, continues to drive innovation in oncology and rare diseases amid key patent expirations. US investors track its robust dividend and exposure to the $500B+ US biologics market.

Amgen Inc. remains a cornerstone in the US biotechnology sector, with recent developments highlighting its strategic focus on high-growth areas like obesity treatments and oncology. The company reported steady progress in its pipeline, including updates on key drug candidates, as shared in its latest investor communications available on its investor relations site as of 05/12/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, Europe, Japan
• Key revenue drivers: Oncology, cardiovascular, inflammation drugs
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen Inc. pioneered the biotech industry with recombinant DNA technology, launching blockbuster drugs like Epogen and Neupogen in the 1980s. Today, it operates as a fully integrated biopharmaceutical company, focusing on discovering, developing, manufacturing, and delivering human therapeutics worldwide. Its model emphasizes large-molecule biologics, which account for the majority of its revenue, per its 2024 annual report published on investors.amgen.com as of 02/07/2025.

The company's strategy centers on three pillars: innovative medicines in high-unmet-need areas, operational excellence, and a strong balance sheet supporting R&D and shareholder returns. Amgen invests approximately 20% of sales in research and development annually, funding a pipeline of over 20 investigational products as of Q1 2026 filings.

Main revenue and product drivers for Amgen Inc.

Prolia and Xgeva, its bone health franchise, generated $3.8 billion in global sales for the 12 months ended December 31, 2024, according to Amgen's annual report released February 7, 2025. Oncology leaders like Kyprolis and Lumakras contribute significantly, with the latter targeting KRAS-mutated lung cancers—a segment growing rapidly in the US market.

Enbrel, a TNF inhibitor for autoimmune diseases, remains a key earner despite biosimilar competition, posting $3.1 billion in 2024 sales. Emerging drivers include MariTide, an obesity candidate in Phase 3 trials, positioning Amgen in the booming GLP-1 market dominated by US players like Eli Lilly and Novo Nordisk.

Industry trends and competitive position

The US biotech sector, valued at over $500 billion in market cap as of 2026 per S&P Global data published March 2026, faces patent cliffs but benefits from IRA-driven pricing reforms and AI-accelerated drug discovery. Amgen holds a top-5 position by revenue, with superior free cash flow enabling $5 billion+ annual dividends and buybacks.

Competitors like Regeneron and Gilead challenge in oncology, but Amgen's scale—serving 10 million+ US patients yearly—provides a moat. Its US-centric revenue (over 60%) ties it closely to American healthcare spending trends.

Why Amgen Inc. matters for US investors

Listed on Nasdaq, Amgen offers US investors direct exposure to biotech innovation fueling the $1.5 trillion US healthcare economy. Its products treat prevalent conditions like osteoporosis and cancer, aligning with aging demographics—US over-65 population projected to hit 83 million by 2050 per Census Bureau 2024 report.

With consistent dividends yielding around 3% and Nasdaq liquidity, Amgen suits dividend-growth strategies amid volatile small-cap biotechs.

Conclusion

Amgen Inc. exemplifies resilient biotech leadership, balancing mature franchises with pipeline innovation amid industry headwinds. US investors value its market position, cash generation, and relevance to domestic healthcare trends. Ongoing developments in obesity and oncology warrant monitoring via official channels.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.